Aaron Wealth Advisors LLC Sells 15,498 Shares of Amgen Inc. $AMGN

Aaron Wealth Advisors LLC cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 165,841 shares of the medical research company’s stock after selling 15,498 shares during the quarter. Amgen comprises 3.0% of Aaron Wealth Advisors LLC’s holdings, making the stock its 7th biggest position. Aaron Wealth Advisors LLC’s holdings in Amgen were worth $54,281,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in AMGN. Board of the Pension Protection Fund acquired a new position in shares of Amgen in the 4th quarter worth approximately $26,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen in the 2nd quarter worth approximately $32,000. Olistico Wealth LLC acquired a new position in shares of Amgen in the 4th quarter worth approximately $33,000. Cloud Capital Management LLC acquired a new position in shares of Amgen in the 3rd quarter worth approximately $34,000. Finally, Saranac Partners Ltd acquired a new position in shares of Amgen in the 3rd quarter worth approximately $37,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

AMGN opened at $342.57 on Tuesday. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The company has a fifty day simple moving average of $363.51 and a 200 day simple moving average of $333.65. The stock has a market cap of $184.67 billion, a P/E ratio of 24.07, a P/E/G ratio of 3.45 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the prior year, the company earned $5.31 EPS. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

Analysts Set New Price Targets

Several brokerages have recently commented on AMGN. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Wells Fargo & Company boosted their price objective on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 19th. Freedom Capital cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Cantor Fitzgerald boosted their price objective on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Finally, Rothschild & Co Redburn boosted their price objective on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $354.60.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.